Weighing up CV endpoints

Although FDA's Cardiovascular and Renal Drugs Advisory Committee panel on Jan. 15 was focused on Merck & Co. Inc.'s Zontivity vorapaxar, the agency asked how CV outcomes should be measured in the future.